BioCryst Pharmaceuticals, Inc.

Contributing Author

Recent Articles by BioCryst Pharmaceuticals, Inc.

4 hours	BioCryst to Present at Upcoming Investor Conference BCRX GlobeNewswire
Aug-11	BioCryst Announces Departure of Dr. Helen Thackray BCRX GlobeNewswire
Aug-06	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Aug-04	BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update BCRX GlobeNewswire
Jul-31	BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December BCRX GlobeNewswire
Jul-21	BioCryst to Report Second Quarter 2025 Financial Results on August 4 BCRX GlobeNewswire
Jul-09	BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit BCRX GlobeNewswire
Jul-07	BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development BCRX GlobeNewswire
Jul-03	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Jun-27	BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million BCRX GlobeNewswire
Jun-16	BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO (berotralstat) Across all Ages at EAACI BCRX GlobeNewswire
Jun-13	ORLADEYO (berotralstat) Approved in Colombia BCRX GlobeNewswire
Jun-06	BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries BCRX GlobeNewswire
Jun-03	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire
Jun-02	BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology BCRX GlobeNewswire
May-30	BioCryst Highlights Real-world Data Showing ORLADEYO (berotralstat) Consistently Reduces HAE Attacks Across All Ages BCRX GlobeNewswire
May-27	BioCryst to Present at Upcoming Investor Conferences BCRX GlobeNewswire
May-16	BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO (berotralstat) BCRX GlobeNewswire
May-14	BioCryst Announces FDA Acceptance of NDA for ORLADEYO (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years BCRX GlobeNewswire
May-05	BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update BCRX GlobeNewswire
May-02	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BCRX GlobeNewswire

BioCryst Pharmaceuticals, Inc.

Recent Articles by BioCryst Pharmaceuticals, Inc.

Upgrade your FINVIZ experience